BioNano Genomics Inc vs Global X SuperDividend ETF — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.20M), while Global X SuperDividend ETF trades at $24.9. The key difference: Global X SuperDividend ETF is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | SDIV | |
|---|---|---|
Market Cap | $13.20M | — |
Sector | Health | Broad Market / Factor |
52-Week High | $4.92 | $26.34 |
52-Week Low | $1.09 | $22.90 |
Enterprise Value | $15.81M | — |
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
SDIV trades at $24.52, down 0.33% today, with a neutral technical signal overall. The ETF maintains a consistent dividend payout of $0.18 per share, with recent distributions in May and June 2026. Technical indicators show mixed signals with bearish moving averages but neutral oscillators, while support and resistance cluster around $24-$25. Recent news highlights SDIV's appeal for income investors seeking diversification from tech-heavy portfolios.
SDIV offers investors exposure to high-yield global equities with minimal technology exposure, providing diversification benefits. The 9.29% yield remains attractive for income-focused portfolios, though the fund's heavy weighting in financials and energy sectors introduces sector concentration risks. Current technical positioning suggests limited near-term price movement potential.
Trailing returns across standard periods
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →SDIV is an ETF that invests in 100 of the highest dividend-yielding equity securities in the world. The fund seeks to provide a high level of income to investors by selecting companies from both developed and emerging markets that have historically provided high dividend yields. By diversifying globally, SDIV aims to mitigate risks associated with focusing on a single country, while offering monthly distributions to its shareholders.
Read more on SDIV →